Drug news
Moxetumomab (MedImmune/AstraZeneca) moves into Phase III for Treatment of Hairy Cell Leukemia
MedImmune, AstraZeneca�s global biologics research and development arm, has enrolled the first patient in the Phase III clinical trial for moxetumomab pasudotox. The trial is sponsored by the Cancer Therapy Evaluation Program (CTEP), a programme within the Division of Cancer Treatment and Diagnosis at the US National Cancer Institute, and will evaluate moxetumomab pasudotox as a potential treatment in adult patients with Hairy Cell Leukaemia who have not responded to or relapsed after standard therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.